课题基金 / 基金详情

Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound

Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound
血浆淀粉样β肽、居家中的抑郁症和阿尔茨海默病
批准号:
7646732
负责人:
WEI QIAO Wendy QIU
金额:
$41.76万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-15 至 2009-11-30

项目摘要

项目成果

WEI QIAO Wendy QIU的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Both Alzheimer?s disease (AD) and depression have become increasingly more prevalent in the homebound elderly, leading to increased rates of morbidity, nursing home placement and mortality, than what are found in the general elderly population. Our cross-sectional study of an established homebound population in the Boston area has found that low plasma amyloid-a42 (Aa42) is associated with depression independently of cardiovascular disease. We further found that depression with low Aa42 combined with high Aa42 in plasma is associated with poor memory. Similarly other research studies have shown that a high plasma Aa40/Aa42 ratio significantly increased the risk of AD. Multiple studies demonstrate that plasma Aa correlates with cerebral spinal fluid (CSF) Aa when cognition is normal, but this equilibrium disappears after the AD cognitive symptoms occur. We hypothesize the existence of a potential depression subtype associated with Ab peptides in plasma, which we have termed ?amyloid-associated depression?. The purpose of this R01 application is to validate the existence of amyloid-associated depression defined by a high plasma Aa40/Aa42 ratio, and to investigate whether this depression subtype is a prodromal depression of AD. The proposal is based on our established population, and has two aims: Aim 1 is to document memory decline prospectively in those with amyloid-associated depression vs. those with non-amyloid depression vs. the controls. Aim 2 is to investigate the relationship between plasma Aa and CSF Aa, a central nervous system (CNS) biomarker of AD, in the different depression subgroups. Our long-term goal is to identify prodromal signs of AD to help facilitate early treatment of the disease in the homebound elderly population. PUBLIC HEALTH RELEVANCE: The proposed longitudinal study seeks to validate amyloid associated depression by investigating whether the combination of depression and a high plasma Aa40/Aa42 ratio will lead to greater risk of cognitive decline and the finding of the AD biomarkers in CSF as compared to those with a low plasma Aa40/Aa42 ratio or those without depression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
  • 批准号:
    10670352
  • 项目类别:
  • 资助金额:
    $49.89万
  • 财政年份:
    2020
  • 负责人:
    WEI QIAO Wendy QIU
  • 依托单位:
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
  • 批准号:
    10256774
  • 项目类别:
  • 资助金额:
    $38.59万
  • 财政年份:
    2020
  • 负责人:
    WEI QIAO Wendy QIU
  • 依托单位:
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
  • 批准号:
    10047359
  • 项目类别:
  • 资助金额:
    $40.08万
  • 财政年份:
    2020
  • 负责人:
    WEI QIAO Wendy QIU
  • 依托单位:
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
  • 批准号:
    10468285
  • 项目类别:
  • 资助金额:
    $50.64万
  • 财政年份:
    2020
  • 负责人:
    WEI QIAO Wendy QIU
  • 依托单位: